| 초록 |
Every year thousands of bone cancer cases are diagnosed in United States. According to the American Cancer Society, an estimated 3,300 new cases of bone cancer are expected to occur during 2016. Moreover, development of bone metastasis occurs in over 80% to 90% of various cancers that metastasize and signals the entry of the disease into an incurable phase. Cancer in bones can cause pain, fractures, hypercalcaemia, and tumor compression of the spinal cord, due to cancer deposits that can erode into bone using bone-absorbing cells. To date, limited treatment options exist for bone cancer. The difficulty of eliminating bone-residing cancer necessitates an alternative novel diagnostic combinatorial treatment regimen to manipulate drug resistance and microenvironment of tumor cells with minimal off-target effects. Bisphosphonates are drugs that reduce the activity of bone-absorbing cells and target over expressed calcium. Herein, we engineered bone-homing polymeric nanomedicine for controlled delivery of therapeutics to bone. Two different strategies to engineer bone microenvironment targeted polymeric nanomedicine will be discussed in this presentation. First, nanomedicine was engineered from the ring opening polymerization of cyclic lactone (L-lactide) initiated by calcium protected alendronic acid, a member of bisphosphonate. Second, nanomedicine was engineered as a lipid polymer hybrid nanomedicine, which is decorated with phospholipid conjugated alendronic acid. We will discuss the in-vitro targeting efficiency and its ability to load chemotherapeutics and magnetic resonance (MR) contrast agent for therapy and MR imaging application. |
